V. Valotassiou, S. Archimandritis, N. Sifakis, J. Papatriantafyllou and P. Georgoulias Pages 477 - 486 ( 10 )
The definite diagnosis of Alzheimers disease (AD) is based on the detection of beta amyloid (Aβ) plaques and neurofibrillary tangles (NFTs) - which are the pathological hallmarks of the disease- in the postmortem brains. Although regional Cerebral Blood Flow (rCBF) and Cerebral Glucose Metabolism (CGM) abnormalities have already been studied in AD patients with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET), the development of specific imaging agents for direct mapping of Aβ plaques in the living brain, is a great challenge. Aβ probes could significantly contribute to the early diagnosis of AD, the elucidation of the underlying neuropathological processes and the evaluation of anti-amyloid therapies which are currently under investigation. The development of SPECT and PET tracers for Aβ imaging represents an active area in radiopharmaceutical design. A substantial number of potential Aβ imaging radioligands have been designed and used in-vitro. They are either monoclonal antibodies to Aβ and radiolabeled Aβ peptides, or derivatives of histopathological stains such as Congo red (CR), chrysamine-G (CG) and Thioflavin T (TT). Though, only few of them, that display high binding affinity to Aβ as well as sufficient brain penetration, have been used primarily in in-vivo studies and to a smaller degree on human subjects. Since Aβ plaques are not homogenous and contain multiple binding sites that can accommodate structurally diverse compounds, they offer flexibility in designing various different probes, as potential amyloid imaging agents.
Alzheimer's Disease, Beta Amyloid, SPECT, PET
Nuclear Medicine Dept., University of Thessaly, University Hospital of Larissa, Mezourlo Larissa 41110 Hellas, Greece.